Safimestomig (6MW3211) is an CD47/PD-L1 -targeting bispecific antibody. Safimestomig blocks CD47-mediated 'don't eat me' signaling and selectively binds to CD47 on tumor cells. Safimestomig blocks PD-L1-mediated immune checkpoint signaling. Safimestomig can be used for the research of cancer [1].
In Vitro, Safimestomig is a CD47/PD-L1 bispecific antibody that selectively binds CD47 on tumor cells, not on red blood cells[1].
References:
[1]. Yang Y, et al. Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy. Mol Ther Oncolytics. 2023;31:100747. Published 2023 Nov 4.
In Vitro, Safimestomig is a CD47/PD-L1 bispecific antibody that selectively binds CD47 on tumor cells, not on red blood cells[1].
References:
[1]. Yang Y, et al. Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy. Mol Ther Oncolytics. 2023;31:100747. Published 2023 Nov 4.